CORRELATION BETWEEN B23 AND THE CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS OF GLIOMA

Zhaozhe Chen*, #, Huanhuan Huang**, Yongchao Mao***

*Shangrao Fifth People's Hospital, Shangrao, PR China - **Qingshan Lake Traditional Chinese Medicine Hospital, Hangzhou, PR China - ***Department of Surgery, Third People's Hospital of Huanghu Branch, Hangzhou, PR China

Objective: To study the correlation between B23 and the clinicopathological features and prognosis of glioma. 

Methods: Ninety-two cases of glioma histopathological paraffin specimens and twenty-five cases of glioma-free paracancerous tissues in the pathology department of our hospital were collected from March 2017 to December 2018. Two-step immunohistochemistry and Western blot were used to detect the expression of nucleolar phosphoprotein (B23) in glioma tissues and paracancerous tissues, and the correlation between its expression and the clinicopathological features and prognosis of glioma was analysed. 

Results: The expression level of B23 in glioma tissues with grade II, III, and IV was significantly higher than that in normal adjacent tissues, and the level in grade IV was significantly higher than that in II and III (P<0.05). The expression level of B23 was correlated with the TNM stage of glioma patients (P<0.05), and in grade II, that was significantly lower than that of grade III and IV (P<0.05). B23 expression was not associated with age, gender, tumour location, resection range, and tumour size (P>0.05). The 5-year survival rate of B23 patients with high expression was 16.23%, which was significantly lower than that of B23 patients with low expression at 68.90% (P<0.05). Survival analysis of glioma patients using the Cox proportional hazard model showed that B23 expression in gliomas was an independent risk factor for the prognosis of patients with glioma; age, sex, tumour location, resection range, and tumour size are not independent risk factors for the prognosis of patients with glioma. 

Conclusion: B23 shows a high expression state in glioma tissues, and its expression is closely related to the World Health Organization (WHO) stage. High expression of B23 may indicate poor prognosis in patients with glioma and can be used as an important reference for the diagnosis and evaluation of prognosis in patients with glioma.